Abstract
Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable
Original language | English |
---|---|
Pages (from-to) | 521-528pp |
Journal | International Journal of Technology Assessment in Health Care |
Volume | 33 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2017 |